NI201200027A - ANTIBODIES AGAINST THE EXT - Google Patents

ANTIBODIES AGAINST THE EXT

Info

Publication number
NI201200027A
NI201200027A NI201200027A NI201200027A NI201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A NI 201200027 A NI201200027 A NI 201200027A
Authority
NI
Nicaragua
Prior art keywords
erbb3
antibodies
antigen
receptor
binding fragments
Prior art date
Application number
NI201200027A
Other languages
Spanish (es)
Inventor
Schoeberl Birgit
Nielsen Ulrik
Feldhaus Michael
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201200027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of NI201200027A publication Critical patent/NI201200027A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una nueva clase de anticuerpos y fragmentos de unión a antígeno de los mismos que se unen al dominio extracelular del receptor ErbB3 e inhiben diversas funciones de ErbB3. Por ejemplo, los anticuerpos y fragmentos de unión a antígeno descritos en la presente son capaces de unirse al receptor designado ErbB3 e inhibir la fosforilación mediada por ligando similar a EGF del receptor. Dichos anticuerpos y fragmentos de unión a antígeno de los mismos tiene la característica útil de inhibir la proliferación de células cancerígenas que expresan ErbB3.The present invention provides a new class of antibodies and antigen-binding fragments thereof that bind to the extracellular domain of the ErbB3 receptor and inhibit various functions of ErbB3. For example, the antibodies and antigen-binding fragments described herein are capable of binding to the designated receptor ErbB3 and inhibiting EGF-like ligand-mediated phosphorylation of the receptor. Said antibodies and antigen-binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

NI201200027A 2009-08-21 2012-02-15 ANTIBODIES AGAINST THE EXT NI201200027A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21

Publications (1)

Publication Number Publication Date
NI201200027A true NI201200027A (en) 2013-01-29

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201200027A NI201200027A (en) 2009-08-21 2012-02-15 ANTIBODIES AGAINST THE EXT

Country Status (21)

Country Link
EP (1) EP2467164A2 (en)
JP (1) JP5752687B2 (en)
KR (1) KR20120059568A (en)
CN (1) CN103002912A (en)
AU (1) AU2010284018C1 (en)
BR (1) BR112012003809A2 (en)
CA (1) CA2771744A1 (en)
CR (1) CR20120108A (en)
DO (1) DOP2012000044A (en)
EA (1) EA201200195A1 (en)
EC (1) ECSP12011740A (en)
IL (1) IL218097A0 (en)
IN (1) IN2012DN01518A (en)
MA (1) MA33582B1 (en)
MX (1) MX336091B (en)
NI (1) NI201200027A (en)
PE (1) PE20121585A1 (en)
SG (1) SG178509A1 (en)
TN (1) TN2012000057A1 (en)
WO (1) WO2011022727A2 (en)
ZA (1) ZA201201195B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2129396T3 (en) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antibodies to ErbB3 and uses thereof
ES2655737T3 (en) 2009-11-13 2018-02-21 Daiichi Sankyo Europe Gmbh Materials and methods to treat or prevent diseases associated with HER-3
CA2782571C (en) 2009-12-22 2018-01-23 Roche Glycart Ag Anti-her3 antibodies and uses thereof
NZ602084A (en) 2010-03-11 2014-07-25 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
ES2566602T3 (en) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
UA114883C2 (en) 2010-08-20 2017-08-28 Новартіс Аг Antibodies for epidermal growth factor receptor 3 (her3)
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
IT1402149B1 (en) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS.
DK2635604T3 (en) 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
TWI631136B (en) 2011-04-19 2018-08-01 莫瑞麥克製藥公司 Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
AU2012274461A1 (en) * 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
KR20140069331A (en) 2011-09-30 2014-06-09 리제너론 파아마슈티컬스, 인크. ANTI-ErbB3 ANTIBODIES AND USES THEREOF
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2764364B1 (en) 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
CN104011079B (en) * 2011-11-09 2017-06-16 Uab研究基金会 HER3 antibody and application thereof
UY34487A (en) 2011-12-05 2013-07-31 Novartis Ag ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEIVER 3 (HER3)
JP2015509492A (en) * 2012-02-22 2015-03-30 ユー３・ファーマ・ゲーエムベーハー Combination of HB-EGF binding protein and EGFR inhibitor
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
ES2816624T3 (en) * 2014-02-28 2021-04-05 Merus Nv Antibodies that bind EGFR and ERBB3
CN105367657B (en) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 Anti- HER3 antibody, its preparation method and its application
EP3191523B1 (en) 2014-09-08 2019-08-07 Yeda Research and Development Co., Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP3912998A3 (en) 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
JP2020511993A (en) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells carrying the NRG1 fusion gene
EP3665200A4 (en) 2017-08-09 2021-04-28 University of Saskatchewan Her3 binding agents and uses thereof
WO2019031965A1 (en) 2017-08-09 2019-02-14 Merus N.V. Antibodies that bind egfr and cmet
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
WO2019241893A2 (en) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anti-her3 antibody and uses thereof
CN116133694A (en) * 2020-10-14 2023-05-16 江苏恒瑞医药股份有限公司 anti-HER 3 antibody and anti-HER 3 antibody drug conjugate and medical application thereof
WO2023198138A1 (en) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Antibody or antigen-binding fragment thereof and medical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2129396T3 (en) * 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antibodies to ErbB3 and uses thereof

Also Published As

Publication number Publication date
WO2011022727A3 (en) 2013-06-27
MX2012002172A (en) 2012-05-29
PE20121585A1 (en) 2012-11-29
EP2467164A2 (en) 2012-06-27
CN103002912A (en) 2013-03-27
IN2012DN01518A (en) 2015-06-05
TN2012000057A1 (en) 2013-09-19
AU2010284018A1 (en) 2012-03-22
JP5752687B2 (en) 2015-07-22
CA2771744A1 (en) 2011-02-24
EA201200195A1 (en) 2012-12-28
BR112012003809A2 (en) 2019-09-24
AU2010284018B2 (en) 2014-06-05
KR20120059568A (en) 2012-06-08
SG178509A1 (en) 2012-04-27
CR20120108A (en) 2012-06-05
AU2010284018C1 (en) 2015-10-15
IL218097A0 (en) 2012-04-30
DOP2012000044A (en) 2012-06-30
MX336091B (en) 2016-01-08
ECSP12011740A (en) 2013-02-28
JP2013506622A (en) 2013-02-28
MA33582B1 (en) 2012-09-01
WO2011022727A2 (en) 2011-02-24
ZA201201195B (en) 2015-07-29

Similar Documents

Publication Publication Date Title
NI201200027A (en) ANTIBODIES AGAINST THE EXT
ECSP099637A (en) ANTIBODIES AGAINST ERBB3 AND THE USES OF THE SAME
CY1119154T1 (en) ANTI-VLA-4 ANTIBODIES
CY1121862T1 (en) ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
CY1122898T1 (en) EXCRETION OF HEME-CONTAINING POLYPEPTIDES
TR201905458T4 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of their use.
MX2019012953A (en) Bispecific antibody against ox40 and ctla-4.
CR20140146A (en) ANTI-BODIES ANTI-CD134 (OX40) AND USES OF THE SAME
CR20150493A (en) AMRI COMPOSITIONS AGAINST COMPONENT C5 OF THE COMPLEMENT AND METHODS FOR USE
CL2017002641A1 (en) Bispecific antibody constructs against cdh3 and cd3
CR20140585A (en) ST2 ANTIGEN UNION PROTEINS
MX2015012122A (en) Antibody drug conjugates and corresponding antibodies.
CO7151527A2 (en) Anti-CD79 B and Immunoconjugate Antibodies
NZ710929A (en) Antibody drug conjugates
CR20150634A (en) HETEROAROMATIC COMPOUNDS AND ITS USE AS DOPAMINE LIGANDS D1
WO2018151841A8 (en) Multispecific binding molecules having specificity to dystroglycan and laminin-2
TR201910959T4 (en) Application of electromagnetic radiation to the human iris.
CO7151529A2 (en) Anti-CD22 and immunoconjugate antibodies
IN2014DN05885A (en)
NI201800134A (en) ANTIBODIES ANTIFACTOR OF COAGULATION XI
CO2020006453A2 (en) Anti-cxcr5 antibodies and compositions and uses thereof
CO7240413A2 (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
PE20151164A1 (en) BMP-6 ANTIBODIES
MX2016000344A (en) Immunoglobulin fc conjugate maintaining fcrn binding strength.
BR112017002755A2 (en) antibodies directed against the fc gamma iib receptor and the fc epsilon receptor